Stryker Company Profile (NYSE:SYK)

Stryker trades on the New York Stock Exchange (NYSE) under the ticker symbol "SYK."

Stryker declared a quarterly dividend on Wednesday, May 17th. Shareholders of record on Friday, June 30th will be paid a dividend of $0.425 per share on Monday, July 31st. This represents a $1.70 annualized dividend and a yield of 1.20%. The ex-dividend date is Wednesday, June 28th. View Stryker's Dividend History.

Stryker Co. (NYSE:SYK) released its earnings results on Tuesday, April, 25th. The company reported $1.48 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.43 by $0.05. The company had revenue of $2.96 billion for the quarter, compared to the consensus estimate of $2.90 billion. Stryker had a return on equity of 23.86% and a net margin of 14.54%. The company's quarterly revenue was up 18.4% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.24 earnings per share. View Stryker's Earnings History.

Stryker is scheduled to release their next quarterly earnings announcement on Wednesday, July, 19th 2017. View Earnings Estimates for Stryker.

Stryker issued an update on its FY17 earnings guidance on Tuesday, April, 25th. The company provided earnings per share guidance of $6.35-6.45 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $6.41. The company issued revenue guidance of +5.5-6.5% (Approx $11.89-12.06 billion), compared to the consensus revenue estimate of $12.17 billion.Stryker also updated its Q2 guidance to $1.48-1.52 EPS.

19 analysts have issued 12-month price objectives for Stryker's stock. Their forecasts range from $119.00 to $150.00. On average, they anticipate Stryker's share price to reach $135.38 in the next year. View Analyst Ratings for Stryker.

Here are some recent quotes from research analysts about Stryker stock:

• 1. Needham & Company LLC analysts commented, "SYK’s 1Q17 revenue and EPS beat consensus and management maintained guidance. SYK’s organic revenue growth accelerated to 8.2% from 6.7% in 4Q16 although an extra selling day added ~1% to growth (the next two quarters each have one less selling day). MedSurg saw the biggest improvement in organic growth and SYK placed 18 Mako systems which beat our estimate of 13." (4/26/2017)
• 2. According to Zacks Investment Research, "In the past six months, Stryker has outperformed the broader industry trend with respect to price performance. Additionally, a positive estimate revision trend is likely to boost opportunities for the company going ahead. Stryker ended the third quarter of 2016 on a solid note, squarely beating the Zacks Consensus Estimate. Growing adoption of MAKO robots will drive sales in the orthopedic and reconstructive surgery market. Additionally, the acquisition of Sage Products and Physio Control and the recent tie up with Indo UK Institute of Health’s Medicity Program are positives. However, on the flip side, China might prove to be a challenging market for the company. Coming to supply side headwinds, the company has been grappling with supply issues in the spine business for long. We believe this may prove to be a major drawback in the quarters ahead." (12/6/2016)

Some companies that are related to Stryker include Abbott Laboratories (ABT), Boston Scientific (BSX), Intuitive Surgical (ISRG), Zimmer Biomet Holdings (ZBH), Edwards Lifesciences Corp (EW), Smith & Nephew plc (SNN), Hologic (HOLX), Align Technology (ALGN), ResMed (RMD), Varian Medical Systems (VAR), Steris PLC (STE), ABIOMED (ABMD), Masimo (MASI), NuVasive (NUVA), Globus Medical (GMED), Wright Medical Group (WMGI), Nevro Corp (NVRO) and NxStage Medical (NXTM).

Stryker's stock is owned by many different of institutional and retail investors. Top institutional investors include Greenleaf Trust (6.70%), Vanguard Group Inc. (6.27%), BlackRock Inc. (5.89%), State Street Corp (3.63%), Massachusetts Financial Services Co. MA (2.98%) and Bank of New York Mellon Corp (2.65%). Company insiders that own Stryker stock include Glenn S Boehnlein, Howard E Cox Jr, Katherine Ann Owen, Kevin Lobo, Lonny J Carpenter, Louise Francesconi, Roch Doliveux, Ronda E Stryker, Srikant Datar, Timothy J Scannell, William E Berry Jr and Yin C Becker. View Institutional Ownership Trends for Stryker.

Stryker's stock was sold by a variety of institutional investors in the last quarter, including Nordea Investment Management AB, Greenleaf Trust, Tukman Grossman Capital Management Inc., Massachusetts Financial Services Co. MA, Yacktman Asset Management LP, Bank of New York Mellon Corp, APG Asset Management N.V. and State Street Corp. Company insiders that have sold Stryker stock in the last year include Howard E Cox Jr, Katherine Ann Owen, Kevin Lobo, Louise Francesconi, Ronda E Stryker, Srikant Datar, Timothy J Scannell and Yin C Becker. View Insider Buying and Selling for Stryker.

Stryker's stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Vanguard Group Inc., PNC Financial Services Group Inc., SG Americas Securities LLC, Morgan Stanley, Swiss National Bank, Pictet Asset Management Ltd. and Teacher Retirement System of Texas. View Insider Buying and Selling for Stryker.

Shares of Stryker can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Stryker stock can currently be purchased for approximately $141.27.